Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

81. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. (Full text)

Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. There are important differences among guideline recommendations for using statin therapy in primary prevention. New recommendations from the US Preventive Services Task Force (USPSTF) emphasize therapy based on the presence of 1 or more cardiovascular disease (CVD) risk factors and a 10-year global CVD risk of 10% or greater.To (...) determine the difference in eligibility for primary prevention statin treatment among US adults, assuming full application of USPSTF recommendations compared with the American College of Cardiology/American Heart Association (ACC/AHA) guidelines.National Health and Nutrition Examination Survey (NHANES) data (2009-2014) were used to assess statin eligibility under the 2016 USPSTF recommendations vs the 2013 ACC/AHA cholesterol guidelines among a nationally representative sample of 3416 US adults aged 40

2017 JAMA PubMed

82. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study (Full text)

Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study Modern prevention guidelines substantially increase the number of individuals who are eligible for treatment with statins. Efforts to refine statin eligibility via coronary calcification have been studied in white populations but not, to our knowledge, in large African American populations.To compare the relative accuracy of US Preventive Services Task Force (USPSTF (...) , and incident ASCVD (ie, myocardial infarction, ischemic stroke, or fatal coronary heart disease).Of the 2812 included participants, the mean (SD) age at baseline was 55.4 (9.4) years, and 1837 (65.3%) were female. The USPSTF guidelines captured 404 of 732 African American individuals (55.2%) with a CAC score greater than 0; the ACC/AHA guidelines identified 507 individuals (69.3%) (risk difference, 14.1%; 95% CI, 11.2-17.0; P < .001). Statin recommendation under both guidelines was associated with a CAC

2017 JAMA cardiology PubMed

83. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. (Full text)

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk.To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes.Posttrial follow-up

2017 JAMA cardiology PubMed

84. Cholesterol: slightly higher risk of type 2 diabetes with all statins

Cholesterol: slightly higher risk of type 2 diabetes with all statins Prescrire IN ENGLISH - Spotlight ''Cholesterol: slightly higher risk of type 2 diabetes with all statins'', 1 January 2017 {1} {1} {1} | | > > > Cholesterol: slightly higher risk of type 2 diabetes with all statins Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Cholesterol (...) : slightly higher risk of type 2 diabetes with all statins Several large-scale studies have revealed an increased risk of type 2 diabetes in patients taking a statin. Statins are widely used to lower cholesterol, in the hope of reducing the risk of premature death and major cardiovascular events (myocardial infarction, ischaemic stroke). A review has been carried out of 13 studies which included patient follow-up for at least one year. Some 91,000 non-diabetic participants were monitored for 4 years

2017 Prescrire

85. Statins for primary and secondary prevention of cardiovascular disease

Statins for primary and secondary prevention of cardiovascular disease

2017 DynaMed Plus

89. Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins

Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins Article Text Commentary: General medicine Unblinded ASCOT study results do not rule out

2017 Evidence-Based Medicine (Requires free registration)

90. Perspective on Trends in Statin Use (Full text)

Perspective on Trends in Statin Use 27842177 2018 11 13 2380-6591 2 1 2017 Jan 01 JAMA cardiology JAMA Cardiol Perspective on Trends in Statin Use. 11-12 10.1001/jamacardio.2016.4710 Weintraub William S WS Christian Care Health System, Newark, Delaware. eng U54 GM104941 GM NIGMS NIH HHS United States Journal Article United States JAMA Cardiol 101676033 2016 11 15 6 0 2016 11 15 6 0 2016 11 15 6 0 ppublish 27842177 2583423 10.1001/jamacardio.2016.4710 PMC5621636 NIHMS863753 Health Aff (Millwood

2017 JAMA cardiology PubMed

91. Long-term persistence in use of statin therapy in elderly patients. (PubMed)

Long-term persistence in use of statin therapy in elderly patients. Knowledge of long-term persistence with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy is limited because previous studies have observed patients for short periods of time, in closely monitored clinical trials, or in other unrepresentative settings.To describe the patterns and predictors of long-term persistence with statin therapy in an elderly US population.Retrospective cohort study including 34 (...) 501 enrollees in the New Jersey Medicaid and Pharmaceutical Assistance to the Aged and Disabled programs who were 65 years of age and older, initiated statin treatment between 1990 and 1998, and who were followed up until death, disenrollment, or December 31, 1999.Proportion of days covered (PDC) by a statin in each quarter during the first year of therapy and every 6 months thereafter; predictors of suboptimal persistence during each interval (PDC <80%) were identified using generalized linear

2017 JAMA

92. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. (PubMed)

Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Landmark clinical trials have demonstrated the survival benefits of statins, with benefits usually starting after 1 to 2 years of treatment. Research prior to these trials of older lipid-lowering agents demonstrated low levels of 1-year adherence.To compare 2-year adherence following statin initiation in 3 cohorts of patients: those with recent acute coronary syndrome (ACS), those with chronic coronary (...) artery disease (CAD), and those without coronary disease (primary prevention).Cohort study using linked population-based administrative data from Ontario.All patients aged 66 years or older who received at least 1 statin prescription between January 1994 and December 1998 and who did not have a statin prescription in the prior year were followed up for 2 years from their first statin prescription. There were 22,379 patients in the ACS, 36,106 in the chronic CAD, and 85,020 in the primary prevention

2017 JAMA

93. Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study (Full text)

Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study Disease-modifying drugs are not yet available for the management of chronic obstructive pulmonary disease (COPD). HMG-CoA reductase inhibitors (statins) have anti-inflammatory properties and are therefore being considered for use in the management of COPD.Our objective was to examine the association between statin use and COPD-specific outcomes in a real-world setting.This was a retrospective (...) longitudinal dynamic cohort study that used Medicaid claims data from multiple years (2005-2008) to identify patients with newly diagnosed COPD. Statin therapy was determined from the prescription drug file using National Drug Codes (NDCs). COPD-specific outcomes such as hospitalizations and emergency room and outpatient visits were identified based on a primary diagnosis of COPD. Multivariable logistic regressions with inverse probability treatment weights (IPTWs) were used to examine the relationship

2016 Drugs - real world outcomes PubMed

94. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis (Full text)

Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis Patients with rheumatoid arthritis (RA) have decreased survival because of increased cardiovascular risk compared with the general population, and treatment with tocilizumab (TCZ) has been shown to increase lipid levels; however, the relationship between lipids and cardiovascular risk is unknown. This post hoc analysis expanded on previously reported 24-week results by characterizing statin (...) of the intention-to-treat populations in the TCZ-IV and TCZ-SC studies, and results were stratified by concomitant statin use.Data from this descriptive, retrospective, pooled analysis indicated that statins can stabilize lipid levels without a clinically significant increase in adverse events. Approximately 30% of patients in the TCZ treatment arms who never received a statin demonstrated a shift in low-density-lipoprotein cholesterol (LDL-C) from <130 mg/dl at baseline to ≥130 mg/dl at 2 years. However

2016 Rheumatology and therapy PubMed

95. Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence (Full text)

Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence 27838724 2016 12 13 2018 11 13 1538-3598 316 19 2016 Nov 15 JAMA JAMA Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. 1971-1972 10.1001/jama.2016.15212 Gurwitz Jerry H JH Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Fallon Health, and Reliant Medical Group, Worcester, Massachusetts2Division of Geriatric Medicine

2016 JAMA PubMed

96. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. (Full text)

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults.The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment (...) of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events.The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD

2016 JAMA PubMed

97. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. (Full text)

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental LDL-C lowering in statin-treated patients; however, the effects of these drugs on coronary atherosclerosis have (...) not been evaluated.To determine the effects of PCSK9 inhibition with evolocumab on progression of coronary atherosclerosis in statin-treated patients.The GLAGOV multicenter, double-blind, placebo-controlled, randomized clinical trial (enrollment May 3, 2013, to January 12, 2015) conducted at 197 academic and community hospitals in North America, Europe, South America, Asia, Australia, and South Africa and enrolling 968 patients presenting for coronary angiography.Participants with angiographic coronary

2016 JAMA PubMed

98. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. (Full text)

Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy.To systematically review benefits and harms of statins for prevention of CVD to inform the US Preventive Services Task Force.Ovid MEDLINE (from 1946), Cochrane Central Register of Controlled Trials (from 1991 (...) ), and Cochrane Database of Systematic Reviews (from 2005) to June 2016.Randomized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-intensity statins in adults without prior cardiovascular events.One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. Data were pooled using random-effects meta-analysis.All-cause mortality, CVD-related morbidity or mortality

2016 JAMA PubMed

99. Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis (Full text)

Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis OBJECTIVE The efficacy of statin therapy in treating aneurysmal subarachnoid hemorrhage (SAH) remains controversial. In this meta-analysis, the authors investigated whether statin treatment significantly reduced the incidence of cerebral vasospasm and delayed neurological deficits, promoting a better outcome after aneurysmal (...) SAH. METHODS A literature search of the PubMed, Ovid, and Cochrane Library databases was performed for randomized controlled trials (RCTs) and prospective cohort studies investigating the effect of statin treatment. The end points of cerebral vasospasm, delayed ischemic neurological deficit (DIND), delayed cerebral infarction, mortality, and favorable outcome were statistically analyzed. RESULTS Six RCTs and 2 prospective cohort studies met the eligibility criteria, and a total of 1461 patients

2016 EvidenceUpdates PubMed

100. Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study

Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study To identify predictors and protectors for cardiovascular hospitalization in a giant cell arteritis (GCA) population-based cohort.Using the French National Health Insurance system, we included patients with incident GCA from the Midi-Pyrenees region, southern France, from January 2005 to December 2008 and randomly selected 6 controls matched by sex and age at calendar (...) 1000 person-years versus 14.9, 4.6, 6.2, and 2.5 events per 1000 person-years among controls, respectively. In patients with GCA, cardiovascular comorbidities at diagnosis (HR 6.2, 2.0-19.2), age over 77 years (HR 5.0, 1.40-17.54), as well as the cumulative defined daily dose of statins (HR 0.993, 0.986-0.999) were independent predictors for subsequent cardiovascular hospitalization. None of the 25 patients with GCA who were taking platelet aggregation inhibitors experienced a cardiovascular

2016 EvidenceUpdates